CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer	08/07/2015	Registered
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients	15/12/2015	Registered
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma	05/09/2017	Registered
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II	22/04/2016	Registered
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV	30/06/2016	Registered
NeuroEPO in patients with Mild-Moderate Alzheimer's disease	01/02/2017	Registered
NeuroEPO in patients with Parkinson disease stage II-III	01/02/2017	Registered
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)	30/04/2018	Registered
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer	28/11/2016	Registered
Nimotuzumab-pancreatic cancer-adults-Phase IV.	30/04/2017	Registered
Nimotuzumab cold kit for the immunodiagnosis of solid tumors	05/10/2018	Registered
CIMAvax-EGF-Platelets-Adults- Lung Cancer	03/08/2018	Registered
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial	17/10/2018	Registered
VSSP in metastasic renal cell carcinoma	08/08/2018	Registered
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory	09/07/2018	Registered
NeuroEPO in stroke	02/08/2018	Registered
Itolizumab Safety and Efficacy Study in Covid 19	26/03/2021	Registered
VSSP in renal cell carcinoma	08/04/2021	Registered
Itolizumab-Plasmapheresis in patients with COVID-19	30/06/2021	Registered
VSSPs in renal carcinoma.	21/06/2023	Registered

Registered Trials

Registration process

CENTER OF MOLECULAR IMMUNOLOGY

About the RPCEC

Useful resources